NEW YORK, March 15, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on SRNE, ONCE, SYN, and TGTX which can be accessed for free by signing up to www.wallstequities.com/registration. This morning, WallStEquities.com scans Sorrento Therapeutics Inc. (NASDAQ: SRNE), Spark Therapeutics
On Wednesday, shares in San Diego, California-based Sorrento Therapeutics Inc. recorded a trading volume of 1.88 million shares. The stock ended the session 0.65% higher at $7.70. The Company's shares have gained 8.45% in the last month, 220.83% over the previous three months, and 90.12% over the past year. The stock is trading 8.89% above its 50-day moving average and 128.56% above its 200-day moving average. Moreover, shares of Sorrento Therapeutics, which engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide, have a Relative Strength Index (RSI) of 51.56.
On February 28th, 2018, Sorrento Therapeutics and its majority-owned subsidiary, Scilex Pharmaceuticals Inc., received approval from the US FDA for ZTlido™ (lidocaine topical system) 1.8%. ZTlido is indicated for the relief of pain associated with post-herpetic neuralgia (PHN), also referred to as post-shingles pain. Get the full research report on SRNE for free by clicking below at: www.wallstequities.com/registration/?symbol=SRNE
Philadelphia, Pennsylvania headquartered Spark Therapeutics Inc.'s stock closed the day 2.99% higher at $65.53 with a total trading volume of 577,902 shares. The Company's shares have advanced 21.17% in the past month, 37.32% in the previous three months, and 12.83% over the past year. The stock is trading 17.22% above its 50-day moving average. Additionally, shares of Spark Therapeutics, which focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases, have an RSI of 64.62.
On February 21st, 2018, research firm Stifel reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $73 a share to $64 a share.
On February 23rd, 2018, Spark Therapeutics announced that Arlene V. Drack, M.D., associate professor in ophthalmic genetics at the University of Iowa, will present a new, age-stratified analysis of Phase-3 voretigene neparvovec data at the American Association for Pediatric Ophthalmology and Strabismus Annual Meeting on "Year 3 Results and Age-Stratified Analyses for a Phase-3 Trial of Voretigene Neparvovec in RPE65 Mutation-associated Inherited Retinal Disease," on March 22nd, 2018, at 8:45 a.m. ET at the Washington Hilton Hotel in Washington, D.C. Free research on ONCE can be accessed at: www.wallstequities.com/registration/?symbol=ONCE
Shares in Rockville, Maryland headquartered Synthetic Biologics Inc. recorded a trading volume of 712,807 shares. The stock ended yesterday's trading session 1.91% lower at $0.37. The Company's shares are trading below their 50-day moving average by 18.46%. Furthermore, shares of Synthetic Biologics have an RSI of 44.07.
On March 07th, 2018, Synthetic Biologics announced that it has received written communication from NYSE American LLC (the "Exchange"), the Company's current listing exchange, stating that it is not in compliance with certain continued listing standards as set forth in the NYSE American Company Guide. In order to maintain its listing, the Company intends to submit a plan of compliance by April 03rd, 2018 addressing how it intends to regain compliance with certain Exchange continued listing standards by September 02nd, 2019. Visit WallStEquities.com now and sign up for the free research on SYN at: www.wallstequities.com/registration/?symbol=SYN
New York headquartered TG Therapeutics Inc.'s stock finished Wednesday's session 0.30% lower at $16.75 with a total trading volume of 1.10 million shares. The Company's shares have advanced 41.35% in the last month, 103.03% over the previous three months, and 27.38% over the past year. The stock is trading above its 50-day and 200-day moving averages by 39.17% and 55.65%, respectively. Additionally, shares of TG Therapeutics have an RSI of 78.62.
On March 08th, 2018, TG Therapeutics announced its financial results for Q4 and year ended December 31st, 2017. For Q4 2017, R&D expenses were $26.0 million; G&A expenses were $5.1 million; and net loss was $30.9 million. For the full year, R&D expenses were $102.5 million, G&A expenses were $16.3 million, and net loss was $118.5 million.
On March 09th, 2018, research firm B. Riley FBR, Inc. reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $21.50 a share to $27 a share. The free technical report on TGTX is available at: www.wallstequities.com/registration/?symbol=TGTX
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/pre-market-technical-scan-on-biotech-equities----sorrento-therapeutics-spark-therapeutics-synthetic-biologics-and-tg-therapeutics-300614479.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...
Find out about travel shots or vaccination before you travel to your destination country. Travel ...
Hay fever is caused by allergy to pollen and is characterized by runny or blocked nose, sneezing, ...View All